Follow us on twitter: @csjmagazine Educational programme for medical
device trainers Medical device educators and trainers are healthcare professionals who work to, promote the care and safety of patients, staff and carers, by ensuring that users of medical devices are fully equipped to safely use technology in the fulfilment of their clinical functions. Represented by the national support body NAMDET (the National Association of Medical Device Educators and Trainers), these professionals perform a crucial role. Recently enacted regulations in the Health and Social Care Act 2008 - Regulated Activities Regulations 2014, places a legal obligation on Trusts to ensure that clinicians can use medical devices ‘correctly’. Trusts are required to prove how training has been identified and delivered on all devices to all staff and, during a CQC assessment, organisations may need to prove compliance and provide evidence of training. NAMDET aims to assist members and their organisations by facilitating: l Reductions in adverse medical device incidents.
l Opportunities for sharing best practice. l Participating in training events. l Cost reductions through utilisation of shared resources.
l Improving staff training and retention. l Introducing recognised career paths. l Implementing national standards for medical device training.
l Improving access to training tools. l Provision of information exchange through its’ member network.
l Audits of Medical Devices Training.
The Association will hold its 5th Annual conference at the Birmingham City Centre, Holiday Inn On Thursday 3 November 2016.
Last year over 150 delegates attended the conference in Manchester and even more are expected at this year’s event. Attending the event will be trainers, medical engineers, risk managers and coordinators. The theme of this year’s conference is ‘Training – Quality Care’. Among the many highlights of the educational programme include a keynote presentation by Dr Tom Clutton Brock, consultant anaesthetist, medical advisor, MHRA, on ‘Where quality Training has improved care – especially with Never events’. There will also be an insight into ‘Scan4Safety and what it means for medical device management’, provided by Sarah Jennings, medical device safety officer and medical equipment sister, Salisbury Foundation Trust; and ‘an update on the ECLIPSE Project’ by Professor Ann Blandford, UCL, London. NAMDET has worked closely with the MHRA for many years on a variety of projects and is actively involved in giving advice, reviewing guidelines and developing national best practice documents. The Medical Device Driving Licence (MDDL) was developed by the Devices Clinical team at the MHRA as a repository for certified training and to help keep medical device e-training information in one safe place. The scheme, which helps medical device users to assess and record aspects of safe device usage, is now managed by NAMDET and an update on this work will be provided at the conference.
NAMDET members include: medical engineers, nursing staff, operating department practitioners, medical device trainers, clinical skills trainers, medical device safety officers, risk and governance managers from NHS, voluntary and private
sectors.For further details, visit:
www.namdet.org
NEWS IN BRIEF
New endoscope repair workshop
Fibertech Medical UK, part of the Avensys UK Group, has opened a new British-owned, state-of-the-art endoscopy workshop – perfectly located, centrally in the Midlands, with the aim of ensuring a rapid turnaround for equipment repair. With extensively trained endoscope technicians, varied agreements are available for all flexible and rigid endoscopes, plus surgical camera equipment. The repair service covers all makes, models and manufacturers – regardless of age.
Acquisition of Intervene Group
The GBUK Group has announced the acquisition of the Intervene Group, adding Intervene’s Enteralok, Surety, ENFit Dash3, NRFit Dash6 and BP Cuffs product ranges to the GBUK Group portfolio. The acquisition completed on 12 September 2016.
Shingles vaccine shows high efficacy
GSK has announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix, showing high efficacy in adults aged 70 years and older that is maintained for at least four years. The results were published in the New England Journal of Medicine (NEJM). The study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.
NEWS
OCTOBER 2016
WWW.CLINICALSERVICESJOURNAL.COM I
13
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
